IL277733B2 - Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells - Google Patents

Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Info

Publication number
IL277733B2
IL277733B2 IL277733A IL27773320A IL277733B2 IL 277733 B2 IL277733 B2 IL 277733B2 IL 277733 A IL277733 A IL 277733A IL 27773320 A IL27773320 A IL 27773320A IL 277733 B2 IL277733 B2 IL 277733B2
Authority
IL
Israel
Prior art keywords
hct
mscs
years
months
patient
Prior art date
Application number
IL277733A
Other languages
English (en)
Hebrew (he)
Other versions
IL277733B1 (en
IL277733A (en
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL277733(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of IL277733A publication Critical patent/IL277733A/en
Publication of IL277733B1 publication Critical patent/IL277733B1/en
Publication of IL277733B2 publication Critical patent/IL277733B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
IL277733A 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells IL277733B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (3)

Publication Number Publication Date
IL277733A IL277733A (en) 2020-11-30
IL277733B1 IL277733B1 (en) 2024-06-01
IL277733B2 true IL277733B2 (en) 2024-10-01

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277733A IL277733B2 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160986A1 (en) * 2016-03-16 2017-09-21 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160986A1 (en) * 2016-03-16 2017-09-21 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONG-TAO LV ET AL.,, TRANSPLANTATION OF HUMAN CORD BLOOD MONONUCLEAR CELLS AND UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS IN AUTISM, 27 August 2013 (2013-08-27) *

Also Published As

Publication number Publication date
CA3096033A1 (en) 2019-10-10
EP3773486A1 (en) 2021-02-17
BR112020020295A2 (pt) 2021-01-12
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
EP3773486B1 (en) 2023-12-06
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
SG11202009805PA (en) 2020-11-27
US12491210B2 (en) 2025-12-09
KR20210031853A (ko) 2021-03-23
WO2019195506A1 (en) 2019-10-10
JP2021520380A (ja) 2021-08-19
ES2968823T3 (es) 2024-05-14
CN112351785A (zh) 2021-02-09
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Sun et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Huang et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy
Schlosser-Brandenburg et al. Influence of nutrition and maternal bonding on postnatal lung development in the newborn pig
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Shamim et al. The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder
Akhlaghpasand et al. Repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells for spastic cerebral palsy: Single-arm safety and preliminary efficacy clinical trial
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
Abi Chahine et al. Stem cells therapy for multiple sclerosis
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Motiwala et al. Human Umbilical Cord Blood Infusions in the Management of Autism Spectrum Disorder
Nath Neuroinfectious Diseases-Case Reports Collection 2021
Alvarado Oligodendrocytes in autoimmune demyelination: Role of the potassium channel Kv1. 4 and interaction with T helper cells
US20210353682A1 (en) Pharmaceutical product for preventing or treating alzheimer's disease
Babinski Allogeneic Mesenchymal Stromal Cell Infusions Are Safe and Effective in Children with Autism Spectrum
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases
González Alvarado Oligodendrocytes in autoimmune demyelination: Role of the potassium channel Kv1. 4 and interaction with T helper cells
Bhuin et al. Quality of Life of Chronic Kidney Disease Patients Attending Dialysis Unit in a Tertiary Care Centre in Purba Bardhaman District of West Bengal: A Cross Sectional Study